a Clinica Pediatrica, Dipartimento di Medicina Clinica e Sperimentale , Azienda Ospedaliero Universitaria di Parma, Università di Parma , Parma , Italy.
b Azienda Ospedaliero-Universitaria "Consorziale-Policlinico", Ospedale Pediatrico Giovanni XXIII , Bari , Italy.
Expert Rev Anti Infect Ther. 2015;13(12):1517-35. doi: 10.1586/14787210.2015.1096775. Epub 2015 Oct 23.
We summarize current evidence and recommendations for the use of probiotics in childhood infectious diseases. Probiotics may be of benefit in treating acute infectious diarrhea and reducing antibiotic-associated diarrhea. Potential benefits of probiotic on prevention of traveler's diarrhea,Clostridium difficile-associated diarrhea, side effects of triple therapy in Helicobacter pylori eradication, necrotizing enterocolitis, acute diarrhea, acute respiratory infections and recurrent urinary tract infections remain unclear. More studies are needed to investigate optimal strain, dosage, bioavailability of drops and tablets, duration of treatment and safety. Probiotics and recombinant probiotic strain represent a promising source of molecules for the development of novel anti-infectious therapy.
我们总结了目前关于益生菌在儿童感染性疾病中应用的证据和建议。益生菌可能对治疗急性感染性腹泻和减少抗生素相关性腹泻有益。益生菌对旅行者腹泻、艰难梭菌相关性腹泻、幽门螺杆菌根除三联疗法的副作用、坏死性小肠结肠炎、急性腹泻、急性呼吸道感染和复发性尿路感染的预防的潜在益处仍不清楚。需要更多的研究来探讨最佳菌株、剂量、滴剂和片剂的生物利用度、治疗持续时间和安全性。益生菌和重组益生菌菌株为开发新型抗感染治疗提供了有前途的分子来源。